A new study reports that a type of cervical cancer that is less amenable to Pap testing is increasing in several subpopulations of women, pointing to the growing importance of human papillomavirus (HPV) testing and vaccination. The study appears early online in Preventive Medicine.
You are here
Squamous Cell Carcinoma
Osaka University-centered study examines large-scale population survey and identifies increase in cervical cancer rate, along with younger patients' surprising resistance to radiation therapy
Cervical cancer rates can be greatly reduced through preventive measures against the human papillomavirus (HPV) along with proactive cancer screening. Japan may be showing how ignoring that knowledge could prove hazardous, as it is the only advanced economy in which the cervical cancer rate is increasing. New research adds further nuance to this situation.
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of Pennsylvania tested the immunotherapy approach in two groups of patients with advanced head and neck squamous cell carcinoma (HNSCCa) and found 86 percent showed elevated T cell activity. It is also the first study to show that the vaccine can help immune cells infiltrate tumors.
A new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked head and neck cancer patients to ensure they remain cancer-free after treatment.
A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Many cancer patients suffer from a loss of body mass known as cachexia. Approximately 20 percent of cancer-related deaths are attributed to the syndrome of cachexia, which in cancer patients is often characterized by a rapid and/or severe loss of fat and skeletal muscle. Dr. Melinda Sheffield-Moore, professor and head of the Department of Health and Kinesiology, along with researchers at University of Texas Medical Branch, recently published research showing that the hormone testosterone is effective at combatting cachexia in cancer patients and improving quality of life.
The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings.
The research, led by Imperial College London, highlights previously unknown skin defenses - and could open avenues for developing new skin cancer treatments.
The early-stage study, published in the journal Nature Immunology, may also provide clues into why allergies are on the rise. Estimates suggest 44 per cent of Britons now suffer from at least one allergy - but the reasons behind the increase are unknown.
Squamous cell carcinoma is the second-most-common form of skin cancer. Evidence suggests the human papilloma virus plays a role in the development of some types of this skin cancer.
Two years ago, a 97-year-old woman whose right leg was covered with squamous cell tumors went to see dermatologist Anna Nichols, M.D., Ph.D., at Sylvester Comprehensive Cancer Center. Surgery is the standard of care for most patients with skin cancer.
Around one in nine men in the US. are infected with oral human papillomavirus (HPV), according to a study led by researchers at the University of Florida.
The infection is much more common among men who have had many oral sexual partners, those who have had sex with men and those who are also infected with genital HPV.